Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $5.4 million.

  • Outlook Therapeutics' Share-based Compensation rose 283.58% to $784,693 in Q3 2020 from the same period last year, while for Sep 2020 it was $2.8 million, marking a year-over-year increase of 113.76%. This contributed to the annual value of $5.4 million for FY2024, which is 2.92% down from last year.
  • Latest data reveals that Outlook Therapeutics reported Share-based Compensation of $5.4 million as of FY2024, which was down 2.92% from $5.5 million recorded in FY2023.
  • Outlook Therapeutics' Share-based Compensation's 5-year high stood at $7.7 million during FY2022, with a 5-year trough of $2.8 million in FY2020.
  • For the 3-year period, Outlook Therapeutics' Share-based Compensation averaged around $6.2 million, with its median value being $5.5 million (2023).
  • As far as peak fluctuations go, Outlook Therapeutics' Share-based Compensation soared by 113.76% in 2020, and later declined by 28.06% in 2023.
  • Over the past 5 years, Outlook Therapeutics' Share-based Compensation (Yearly) stood at $2.8 million in 2020, then spiked by 74.08% to $4.9 million in 2021, then surged by 57.77% to $7.7 million in 2022, then declined by 28.06% to $5.5 million in 2023, then fell by 2.92% to $5.4 million in 2024.